Tubulis

Tubulis is a technology company.

Active

Updated: Feb 17, 2026 ·

Recent News & Mentions

Oct 1, 2025FundingTubulis - Series C Mar 1, 2024FundingTubulis - Series B May 1, 2022FundingTubulis - Series B Jul 1, 2020FundingTubulis - Series A

Financial History

Tubulis has raised $575.0M across 4 funding rounds. Most recently, it raised $360.0M Series C in October 2025.

Total Raised

$575.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Oct 1, 2025	$360.0M Series C	5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures
Mar 1, 2024	$140.0M Series B	5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures
May 1, 2022	$63.0M Series B	5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures
Jul 1, 2020	$12.0M Series A	Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Third Rock Ventures, Venrock

Financial History

Tubulis has raised $575.0M across 4 funding rounds.

Total Raised

$575.0M

Valuation

N/A

Deep Dive

High-Level Overview

Tubulis is a biotechnology company developing antibody-drug conjugates (ADCs) for solid and hematologic tumors, focusing on improved on-tumor delivery and anti-tumor activity through proprietary conjugation technologies.[1][6] It builds advanced ADCs like TUB-040 (targeting NaPi2b for platinum-resistant ovarian cancer and non-small cell lung cancer) and TUB-030 (targeting 5T4 for solid tumors), serving oncology patients and partners such as Bristol Myers Squibb and Gilead Sciences by solving issues like payload instability, off-target toxicity, and resistance in existing ADCs.[2][4][5] Founded in 2020 and based in Planegg-Martinsried, Germany, Tubulis has raised over $575 million across rounds, including a $361 million Series C in 2025, fueling Phase 1/2 trials and preclinical expansion with strong growth momentum evidenced by clinical advancements and partnerships.[1][2]

Origin Story

Tubulis spun out from two German research institutes in 2020, leveraging expertise in protein-drug conjugates to address limitations in ADC design.[2][1] The founding team, led by CEO Dominik Schumacher, emerged from academic and biotech backgrounds focused on tailoring ADC components—such as linkers and payloads—to specific cancers, driven by the need for better tumor targeting amid rising ADC interest.[2] Early traction came from proprietary platforms like Tubutecan and P5 conjugation, leading to rapid patent filings (7 total, covering experimental cancer drugs) and partnerships; a pivotal moment was advancing multiple programs into clinics, including a Bristol Myers Squibb-licensed ADC entering human testing.[1][4][5]

Core Differentiators

Tubulis stands out in the ADC field through its integrated platforms enabling "uniquely matched" conjugates with superior stability and efficacy:

Proprietary Technologies: P5 Conjugation for ultra-stable, high drug-to-antibody ratio (DAR 8) ADCs with antibody-like properties; Tubutecan platform doubles tumor Exatecan exposure versus competitors like Enhertu/Trodelvy, minimizing liver toxicity; Alco5 for stable conjugation of hydroxy payloads like SN38, outperforming existing systems in efficacy and release.[4]
Tailored Optimization: Disease-specific matching of antibodies, linkers, and payloads (e.g., topoisomerase-I inhibitors) for enhanced on-tumor delivery, reduced off-target effects, and durable anti-tumor activity in preclinical models.[1][2][4]
Pipeline Diversity: Proprietary programs (TUB-040 in Phase 1/2, TUB-030 in Phase 1, plus TUB-050/060 and degraders) alongside partnered assets with Bristol Myers Squibb (multi-target) and Gilead (single-target), positioning for resistance solutions.[2][5]
Clinical Edge: Lead TUB-040 targets challenging NaPi2b with a novel linker sidestepping toxicity; interim Phase 1/2 data slated for ESMO 2025.[2]

Role in the Broader Tech Landscape

Tubulis rides the explosive ADC trend, where these "smart bombs" combine antibodies with cytotoxins to precisely kill cancer cells, fueled by approvals like Enhertu and market projections exceeding $20 billion by 2030.[2] Timing is ideal post-2020 spinout amid Big Pharma's ADC frenzy—partnerships with Bristol Myers Squibb and Gilead validate its platforms while Series C funding aligns with clinical readouts.[1][2][5] Favorable forces include advancing topoisomerase-I inhibitors (e.g., Exatecan, SN38) beyond first-gen limitations like instability and resistance, plus novel degraders for new mechanisms.[4] Tubulis influences the ecosystem by licensing tech (e.g., Tubutecan to Bristol Myers) and preempting resistance in ADC-exposed patients, accelerating precision oncology innovation from Europe.[2]

Quick Take & Future Outlook

Tubulis is primed for ADC leadership with TUB-040's Phase 1/2 data at ESMO 2025 potentially catalyzing Phase 3 advancement, alongside TUB-030 readouts and preclinical escalations like degraders.[2][5] Trends like combination therapies, resistance-busting payloads, and AI-optimized conjugates will shape its path, bolstered by $575M+ war chest for scaling manufacturing and trials.[1][2] Its influence may evolve into a platform licensor for Big Pharma, expanding beyond proprietaries to dominate next-gen ADCs—echoing its origin as a spinout innovator now delivering durable tumor-killing precision.

Sources

Frequently Asked Questions

How much funding has Tubulis raised?

Tubulis has raised $575.0M in total across 4 funding rounds.

Who are Tubulis's investors?

Tubulis's investors include 5AM Ventures, Abingworth, Andera Partners, Coparion, EQT Life Sciences, Frazier Healthcare Partners, Hakan Goker, Third Rock Ventures, Venrock, Versant Ventures.